MENU
+Compare
CDXS
Stock ticker: NASDAQ
AS OF
Jan 17, 04:59 PM (EDT)
Price
$5.00
Change
+$0.07 (+1.42%)
Capitalization
406.89M

CDXS Codexis Forecast, Technical & Fundamental Analysis

a developer of biocatalytic chemical processes

Industry Biotechnology
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CDXS with price predictions
Jan 14, 2025

CDXS's Stochastic Oscillator stays in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CDXS advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

CDXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CDXS as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CDXS moved below its 50-day moving average on January 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CDXS entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CDXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.543) is normal, around the industry mean (15.339). P/E Ratio (0.000) is within average values for comparable stocks, (87.552). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.851). CDXS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (5.464) is also within normal values, averaging (263.778).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CDXS is expected to report earnings to fall 87.48% to -3 cents per share on February 26

Codexis CDXS Stock Earnings Reports
Q4'24
Est.
$-0.04
Q3'24
Missed
by $0.05
Q2'24
Missed
by $0.06
Q1'24
Beat
by $0.02
Q4'23
Beat
by $0.02
The last earnings report on October 31 showed earnings per share of -28 cents, missing the estimate of -23 cents. With 638.75K shares outstanding, the current market capitalization sits at 406.89M.
A.I. Advisor
published General Information

General Information

a developer of biocatalytic chemical processes

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Chemicals Specialty
Address
200 Penobscot Drive
Phone
+1 650 421-8100
Employees
174
Web
https://www.codexis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

CDXS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+1.03%
DNLI - CDXS
50%
Loosely correlated
+0.79%
BEAM - CDXS
45%
Loosely correlated
+0.04%
AVIR - CDXS
44%
Loosely correlated
+0.30%
PLRX - CDXS
43%
Loosely correlated
-8.16%
DNA - CDXS
43%
Loosely correlated
+9.68%
More